Article History
Accepted: 23 August 2023
First Online: 3 October 2023
Competing interests
: A.J.S. has served as a consultant to Path‐AI, HistoIndex, Fibronest, Biocellvia, Merck, Pfizer, Eli Lilly, Novo Nordisk, Boehringer Ingelheim, AstraZeneca, Akero, Intercept, Madrigal, Northsea, Takeda, Regeneron, Genentech, Alnylam, Roche, GlaxoSmithKline, Novartis, Tern, Fractyl, Inventiva, Gilead and Target Pharmasolutions, has stock options in Genfit, Tiziana, Durect, Inversago and Hemoshear, and receives royalties from Uptodate and Elsevier. His institution has received grants from Intercept, Pfizer, Merck, Bristol Myers Squibb, Eli Lilly, Novo Nordisk, Boehringer Ingelheim, AstraZeneca, Novartis and Madrigal. Virginia Commonwealth Univerisity has a collaborative agreement with Avant Sante. D.E.K. has uncompensated collaborative projects with HistoIndex and HighTide. P.J. declares no competing interests.